http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011250165-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12451a85531b2598e3d37579cb1222c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f766ff0b7c716d8cc29bcab3fdd3cbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_666d7a2c08201900d5f6f33943f69939 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2006-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_037445809965c1fbc4df4b336b79ba49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dccda4bbac76e90c87f3993fee6a3c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1b228cdd2bc0ba098c220b088716d62 |
| publicationDate | 2011-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2011250165-A1 |
| titleOfInvention | Antibodies against CXCR4 and Methods of Use Thereof |
| abstract | The invention provides human monoclonal antibodies, scFv antibodies, scFv-Fc fusions, a dAb (domain antibodies), F ab , F ab′ and F (ab)′2 fragments, single chain antibodies and/or minibodies that specifically bind to CXCR4. Also provided are methods of treating and/or preventing a CXCR4 disease or disorder such as cancer and X4-tropic HIV-I infection as well as uses of such antibodies and antibody fragments in the manufacture of a medicament for the treatment or prevention of a CXCR4 disorder. The invention also provides methods of preventing diseases or disorders associated with CXCR4 function or expression. The invention further provides for the use of the antibodies (or fragments thereof) of the invention in the manufacture of a medicament for the prevention of diseases or disorders associated with CXCR4 expression. Also provided are methods of treating or preventing cancer metastasis in a patient suffering from a cancer involving tumor cells that express CXCR4. The invention also encompasses the use of such antibodies and antibody fragments in the manufacture of a medicament for the treatment or prevention of cancer metastasis. The invention also includes methods of treating or preventing cancer metastasis in a patient suffering from a hypoxic tumor, such as any solid tumor characterized by HIF-dependent CXCR4 activation. The antibodies and fragments disclosed herein can be used in the manufacture of a medicament for the prevention of cancer metastasis in a patient suffering from a hypoxic tumor. The invention additionally provides methods of mobilizing CD34 + stem cells from the bone marrow as wells methods of blocking chemotaxis of CXCR4-expressing cells in response to SDF-1. Also provided are methods of treating or preventing graft-versus-host disease as well as the use of the antibodies and fragments thereof in the manufacture of a medicament for the prevention or treatment of GVHD. Finally, the invention also provides methods of inhibiting the formation of new tumor blood vessels and/or inhibiting tumor cell angiogenesis. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019178356-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021011480-A1 |
| priorityDate | 2005-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 976.